SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022.
NUPLAZID® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. The improvement was mainly driven by an increase in demand in the long-term care channel and retention of continuing patients across all channels. Overall demand in 2022 was relatively steady compared to the previous year.
“We are poised for a transformative year in 2023. Our increasingly profitable NUPLAZID franchise supports future growth opportunities, including trofinetide - which has the potential to become our second marketed product - as well as the development of our pipeline,” said Steve Davis, Chief Executive Officer. “Last year we submitted our New Drug Application for trofinetide for the treatment of Rett syndrome and we are eager to get to our PDUFA action date of March 12, 2023. Importantly, we also advanced our Phase 3 negative symptoms of schizophrenia program and introduced ACP-204, a new molecule that we plan to evaluate in patients with Alzheimer’s disease psychosis later this year.”
Company Operational, Scientific, and Regulatory Updates
- Trofinetide New Drug Application (NDA) for the treatment of Rett syndrome has an assigned PDUFA action date of March 12, 2023.
- Two large, retrospective analyses of Medicare patients were published in 2022, the first in the American Journal of Psychiatry1 and the second in the journal, Drug Safety2. Both of these analyses found a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID (pimavanserin) when compared to other atypical antipsychotics over the first 180 days and first 12 months, respectively.
- Another large, retrospective analysis of Medicare patients recently published in The Journal of Medical Economics3 found health care resource utilization patterns, such as hospitalizations and ER visits, were lower among patients with PDP treated with NUPLAZID (pimavanserin) when compared to other atypical antipsychotics over 12 months.
- Enrollment is expected to be completed for ADVANCE-2, a Phase 3 study evaluating pimavanserin for the negative symptoms of schizophrenia, around mid-year 2023.
- Doug Williamson, M.D., was appointed as Executive Vice President, Head of Research and Development in January 2023. Dr. Williamson succeeded Dr. Srdjan (Serge) Stankovic who retired at the end of 2022.
Financial Results
Revenue
Net sales of NUPLAZID® (pimavanserin) were $136.5 million for the three months ended December 31, 2022, an increase of 4% as compared to $130.8 million reported for the three months ended December 31, 2021. For the years ended December 31, 2022 and 2021, Acadia reported net product sales of $517.2 million and $484.1 million, respectively, an increase of 7% year-over-year.
Research and Development
Research and development expenses for the three months ended December 31, 2022 were $75.7 million, compared to $67.1 million for the same period of 2021. For the years ended December 31, 2022 and 2021, research and development expenses were $361.6 million and $239.4 million, respectively. The increase in research and development expenses during 2022 was primarily related to a $60 million upfront payment for a collaboration with Stoke Therapeutics, a $10 million milestone payment to our partner, Neuren Pharmaceuticals, upon acceptance of the trofinetide NDA filing, as well as increased costs of manufacturing activities for trofinetide, and the development of early-stage programs, including additional business development activity.
Selling, General and Administrative
Selling, general and administrative expenses for the three months ended December 31, 2022 were $104.4 million, compared to $105.8 million for the same period of 2021. For the years ended December 31, 2022 and 2021, selling, general and administrative expenses were $369.1 million and $396.0 million, respectively. The decrease was related to the continued reduction and optimization of commercial spend related to NUPLAZID, leading to a reduction in overall advertising and promotional costs, offset by investments in preparing for the launch of trofinetide.
Net Loss
For the fourth quarter of 2022, Acadia reported a net loss of $41.7 million, or $0.26 per common share, compared to a net loss of $43.1 million, or $0.27 per common share, for the same period in 2021. The net losses for the fourth quarters of 2022 and 2021 included $14.4 million and $12.9 million, respectively, of non-cash stock-based compensation expense. For the year ended December 31, 2022, Acadia reported a net loss of $216.0 million, or $1.34 per common share, compared to a net loss of $167.9 million, or $1.05 per common share, for the same period in 2021. The net losses for the years ended December 31, 2022 and 2021 included $68.2 million and $63.6 million, respectively, of non-cash stock-based compensation expense.
Cash and Investments
At December 31, 2022, Acadia’s cash, cash equivalents, and investment securities totaled $416.8 million, compared to $520.7 million at December 31, 2021.
2023 Financial Guidance
For the full year 2023, the Company expects:
- Net NUPLAZID sales in the range of $520 to $550 million.
- On a GAAP basis, R&D expense in the range of $235 to $255 million, which includes approximately $20 million of stock-based compensation expense.
- On a GAAP basis, SG&A expense in the range of $360 to $380 million, which includes approximately $45 million of stock-based compensation expense.
Conference Call and Webcast Information
The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. The registration link will also be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until April 3, 2023.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID. In addition, Acadia is developing pimavanserin as a potential treatment for the negative symptoms of schizophrenia.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
About Trofinetide
Trofinetide is an investigational drug. It is a synthetic analog of the tripeptide glycine-proline-glutamate (GPE), a product of the naturally occurring cleavage of insulin-like growth factor 1. Trofinetide is thought to enhance neuronal synaptic function and morphology, supporting its potential role in treating Rett syndrome. This hypothesis is supported by findings from studies of GPE and trofinetide in a Mecp2 mouse model of Rett syndrome, in which increased branching of the dendrites that form synapses and synaptic plasticity signals were observed.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia’s annual report on Form 10-K for the year ended December 31, 2021 as well as Acadia’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
References
1Mosholder AD, Ma Y, Akhtar S, et al. Mortality among Parkinson’s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. Am J Psychiatry. 2022;179(8):553‐561.
2Layton JB, Forns J, McQuay LJ, et al. Mortality in patients with Parkinson’s disease‐related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Safety. 2023;46(2):195-208.
3Rajagopalan K, Rashid N, Kumar S, and Doshi D. Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with Pimavanserin or other-atypical antipsychotics. J Med Econ. 2023;26(1):34-42.
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended December 31, |
|
Years Ended December 31, |
||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
Revenues |
|
|
|
|
|
|
|
|
||||||||
Product sales, net |
|
$ |
136,490 |
|
|
$ |
130,758 |
|
|
$ |
517,235 |
|
|
$ |
484,145 |
|
Total revenues |
|
|
136,490 |
|
|
|
130,758 |
|
|
|
517,235 |
|
|
|
484,145 |
|
Operating expenses |
|
|
|
|
|
|
|
|
||||||||
Cost of product sales, license fees and royalties (1) |
|
|
2,413 |
|
|
|
2,561 |
|
|
|
10,166 |
|
|
|
19,141 |
|
Research and development (1) |
|
|
75,738 |
|
|
|
67,084 |
|
|
|
361,575 |
|
|
|
239,415 |
|
Selling, general and administrative (1) |
|
|
104,402 |
|
|
|
105,770 |
|
|
|
369,090 |
|
|
|
396,028 |
|
Total operating expenses |
|
|
182,553 |
|
|
|
175,415 |
|
|
|
740,831 |
|
|
|
654,584 |
|
Loss from operations |
|
|
(46,063 |
) |
|
|
(44,657 |
) |
|
|
(223,596 |
) |
|
|
(170,439 |
) |
Interest income, net |
|
|
3,630 |
|
|
|
129 |
|
|
|
6,610 |
|
|
|
591 |
|
Other income |
|
|
1,543 |
|
|
|
1,623 |
|
|
|
3,542 |
|
|
|
2,329 |
|
Loss before income taxes |
|
|
(40,890 |
) |
|
|
(42,905 |
) |
|
|
(213,444 |
) |
|
|
(167,519 |
) |
Income tax expense |
|
|
835 |
|
|
|
189 |
|
|
|
2,531 |
|
|
|
351 |
|
Net loss |
|
$ |
(41,725 |
) |
|
$ |
(43,094 |
) |
|
$ |
(215,975 |
) |
|
$ |
(167,870 |
) |
Net loss per common share, basic and diluted |
|
$ |
(0.26 |
) |
|
$ |
(0.27 |
) |
|
$ |
(1.34 |
) |
|
$ |
(1.05 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
161,988 |
|
|
|
160,866 |
|
|
|
161,683 |
|
|
|
160,493 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
(1) Includes the following share-based compensation expenses |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Cost of product sales, license fees and royalties |
|
$ |
93 |
|
|
$ |
261 |
|
|
$ |
1,106 |
|
|
$ |
1,286 |
|
Research and development |
|
$ |
3,432 |
|
|
$ |
4,644 |
|
|
$ |
22,580 |
|
|
$ |
21,969 |
|
Selling, general and administrative |
|
$ |
10,889 |
|
|
$ |
7,975 |
|
|
$ |
44,515 |
|
|
$ |
40,360 |
|
ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||
|
December 31,
|
December 31,
|
||||
|
(unaudited) |
|
||||
Assets |
|
|
||||
Cash, cash equivalents and investment securities |
$ |
416,823 |
|
$ |
520,706 |
|
Accounts receivable, net |
|
62,195 |
|
|
64,366 |
|
Interest and other receivables |
|
885 |
|
|
978 |
|
Inventory |
|
6,636 |
|
|
7,881 |
|
Prepaid expenses |
|
21,398 |
|
|
23,892 |
|
Total current assets |
|
507,937 |
|
|
617,823 |
|
Property and equipment, net |
|
6,021 |
|
|
8,047 |
|
Operating lease right-of-use assets |
|
55,573 |
|
|
58,268 |
|
Restricted cash |
|
5,770 |
|
|
5,770 |
|
Long-term inventory |
|
4,924 |
|
|
6,217 |
|
Other assets |
|
7,587 |
|
|
3,997 |
|
Total assets |
$ |
587,812 |
|
$ |
700,122 |
|
Liabilities and stockholders’ equity |
|
|
|
|||
Accounts payable |
$ |
12,746 |
|
$ |
6,876 |
|
Accrued liabilities |
|
112,884 |
|
|
89,192 |
|
Total current liabilities |
|
125,630 |
|
|
96,068 |
|
Operating lease liabilities |
|
52,695 |
|
|
56,126 |
|
Long-term liabilities |
|
9,074 |
|
|
7,034 |
|
Total liabilities |
|
187,399 |
|
|
159,228 |
|
Total stockholders’ equity |
|
400,413 |
|
|
540,894 |
|
Total liabilities and stockholders’ equity |
$ |
587,812 |
|
$ |
700,122 |
|
